TABLE 5:
Therapeutic area | Percentage mentioned* | Ratio critically important antibiotics (CIAs) v other antibiotics used for treatment | Frequency of citation of the different classes of antibiotics (top 5) |
---|---|---|---|
Skin diseases Including wounds and abscesses |
31% (25%) |
CIAs: 4% Non-CIAs: 96% |
Penicillins 46%, Potentiated sulphonamides 25%, Aminoglycosides 18%, Tetracyclines 5%, 3rd and 4th generation cephalosporins 3% |
Respiratory disease including sinusitis, Streptococcus equi and Rhodococcus equi | 27% |
CIAs: 18% Non-CIAs: 82% |
Penicillins 30%, Potentiated sulphonamides 29%, 3rd and 4th generation cephalosporins 13%, Aminoglycosides 10%, Tetracyclines 7%, |
Locomotion disorders Including arthritis lymphangitis |
10% (5%) (4%) |
CIAs: 9% Non-CIAs: 91% |
Penicillins 42%, Aminoglycosides 31%, Potentiated sulphonamides 10%, Tetracyclines 10%, 3rd and 4th generation cephalosporins 7% |
Perioperative | 9% |
CIAs: 6% Non-CIAs: 94% |
Aminoglycosides 42%, Penicillins 39%, Potentiated sulphonamides 11%, 3rd and 4th generation cephalosporins 4%, (Fluoro)quinolones 2% |
Infections (fever of undefined origin and others, including sepsis and infection) | 8% |
CIAs: 17% Non-CIAs: 83% |
Penicillins 28%, Aminoglycosides 23%, Tetracyclines 16%, Potentiated sulphonamides 13%, 3rd and 4th generation cephalosporins 13% |
Others | 15% |
CIAs: 22% Non-CIAs: 78% |
Penicillins 25%, Aminoglycosides 19%, 3rd and 4th generation cephalosporins 15%, (Fluoro)quinolones 7%, Chloramphenicol 6%, Metronidazole 6%, Fusidic acid 4% |
*Percentages in brackets are part of the percentage mentioned of each therapeutic area.